首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
【24h】

Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.

机译:非典型抗精神病药物治疗香港中国患者的精神分裂症-成本分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To evaluate the direct medical cost of atypical antipsychotic therapy for schizophrenia among Hong Kong Chinese patients and to identify factors affecting the cost of treatment. METHODS: In this retrospective database analysis, patient data were retrieved from three Hong Kong public hospitals. Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included. Patient data were collected for a maximum duration of 1 year before and after treatment initiation. Primary outcome measures were the schizophrenia-related direct medical costs. Demographic and clinical factors were analyzed by multiple regression analysis to identify influential factors for the cost of atypical antipsychotic therapy. RESULTS: A total of 325 patient records were reviewed and 82 patients were included in the analysis. Cost per patient per month for clinic visits (USDollars 67 +/- 41 versus USDollars 78 +/- 41), medications (USDollars 8 +/- 12 versus USDollars 97 +/- 83), and the total cost per patient per month (USDollars 314 +/- 898 versus USDollars 431 +/- 914) increased significantly after treatment initiation (USDollars 1 = HKDollars 7.8). Previous duration of hospitalization (RR = 1.00, 95% CI 1.00 1.01), history of substance abuse (RR and use of depot antipsychotics (RR = 1.22, 95% CI = 1.05 - 1.42) were associated with higher cost of atypical antipsychotic therapy. CONCLUSION: The total direct medical cost increased significantly after initiation of atypical antipsychotic therapy in a cohort of Chinese patients with schizophrenia. History of drug abuse, use of depot antipsychotics and prior duration of hospitalization were positive predictors of cost of therapy.
机译:目的:评估香港中国患者非典型抗精神病药物治疗精神分裂症的直接医疗费用,并确定影响治疗费用的因素。方法:通过回顾性数据库分析,从三家香港公立医院中检索患者数据。 2岁至18岁的患者在2003年4月1日至9月30日期间接受了奥氮平,利培酮,喹硫平或氨磺必利的初次处方;并具有ICD-10编码的精神分裂症诊断。在开始治疗之前和之后,最多收集1年的患者数据。主要结果指标是精神分裂症相关的直接医疗费用。通过多元回归分析分析人口统计学和临床​​因素,以确定非典型抗精神病药物治疗费用的影响因素。结果:共检查了325例患者记录,其中82例患者被纳入分析。每位患者每月的门诊费用(USDollars 67 +/- 41 vs USDollars 78 +/- 41),药物治疗(USDollars 8 +/- 12 vs USDollars 97 +/- 83),以及每位患者每月的总费用(在开始治疗后,USDollars 314 +/- 898与USDollars 431 +/- 914)明显增加(USDollars 1 = HKDollars 7.8)。既往住院时间(RR = 1.00,95%CI 1.00 1.01),药物滥用史(RR和使用抗精神病药库(RR = 1.22,95%CI = 1.05-1.42)与非典型抗精神病药物治疗费用较高相关。结论:在中国精神分裂症患者中,非典型抗精神病药物治疗后直接医疗总费用显着增加,药物滥用史,使用抗精神病药库和住院时间是治疗费用的积极预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号